CEL-SCI Receives U.S. Patent for Use of L.E.A.P.S(TM) Technology for Autoimmune Conditions and Allergies.

Publication: PR Newswire

Bookmark this article Print this article Link to this article Email this article Digg It! Add to del.icio.us RSS

COPYRIGHT 2006 PR Newswire Association LLC

VIENNA, Va., Feb. 28 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION has been issued a U.S. patent covering its L.E.A.P.S.(TM) peptide vaccine technology in the areas of autoimmunity and allergies. The new patent, U.S. Patent No. 6,995,237, is titled, "Preparation and composition of peptides useful for treatment of autoimmune and transplant related graft versus host conditions." The L.E.A.P.S. technology has also produced the patented CEL-1000 drug which induced protection in animals against viruses and parasites and is being tested by the National Institute of Allergy and Infectious Diseases against the avian flu virus.

This new patent builds on work by CEL-SCI scientists in collaboration with scientists from the laboratory of Dr. Noel Rose at The Johns Hopkins University Department of Pathology, showing that pretreatment and...

Read the full article for free courtesy of your local library.